have exploited an innovative and well‐designed shear‐thinning injectable nanogel by simply mixing betamethasone phosphate (BetP), a commonly used anti‐inflammatory drug in clinical settings, anti‐VEGF, the gold‐standard drug for AMD treatment, with CaCl2, totally named BetP‐Gel (Figure 6c).[102] Upon IVT, BetP‐Gel provides sustained release of anti‐VEGF, effectively inhibiting vascular proliferation in the retina and attenuating CNV. Here, VEGFA is linked to age-related macular degeneration.